CIP2A is a target of bortezomib in human triple negative breast cancer cells

INTRODUCTION: Triple negative breast cancer (TNBC) is very aggressive and currently has no specific therapeutic targets, such as hormone receptors or human epidermal growth factor receptor type 2 (HER2); therefore, prognosis is poor. Bortezomib, a proteasome inhibitor, may exert efficacy in TNBC thr...

Descripción completa

Detalles Bibliográficos
Autores principales: Tseng, Ling-Ming, Liu, Chun-Yu, Chang, Kung-Chi, Chu, Pei-Yi, Shiau, Chung-Wai, Chen , Kuen-Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3446403/
https://www.ncbi.nlm.nih.gov/pubmed/22537901
http://dx.doi.org/10.1186/bcr3175

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3446403/
https://www.ncbi.nlm.nih.gov/pubmed/22537901
http://dx.doi.org/10.1186/bcr3175

Ejemplares similares